B和T淋巴细胞衰减蛋白抗体

编号：XY- 0624R

B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Function : Lymphocyte inhibitory receptor which inhibits lymphocytes during immune response.
Subunit : Interacts with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. Interacts with TNFRSF14/HVEM.
Subcellular Location : Membrane; Single-pass type I membrane protein (Potential).
Post-translational modifications : Phosphorylated on Tyr residues by TNFRSF14 and by antigen receptors cross-linking, both inducing association with PTPN6 and PTPN11.
N-glycosylated.
Similarity : Contains 1 Ig-like V-type (immunoglobulin-like) domain.

BTLA对T细胞的活化、增殖起着重要的负调控作用，BTLA相应配体为TNFR超家族中的疱疹病毒入侵介质（HVEM）, 其表达于包括T细胞在内的多种免疫细胞表面。
有学者将他定为CD28的超级族成员，B、T淋巴细胞衰减子-CD272主要用于细胞信号传导方面的研究。
近来国外学者对BTLA用于抑制肿瘤方面的研究也有了新的进展，认为B、T淋巴细胞衰减子对肿瘤的生长有抑制作用，探索新的肿瘤免疫治疗有了新的途径， 封闭此途径有可能成为肿瘤免疫治疗的新靶点。